IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

IGC Pharma (NYSE American: IGC) announced on January 22, 2026 that Integrative Clinical Trials, LLC in Brooklyn, New York, has joined its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) announced on January 22, 2026 that Integrative Clinical Trials, LLC in Brooklyn, New York, has joined its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.

The new site, led by Principal Investigator Dr. Inna Yuryev-Golger, MD, expands the trial's clinical footprint in a major metropolitan area and is expected to support patient enrollment and diversity given the site's CNS research experience. IGC-AD1 is being studied in a randomized, double-blind, placebo-controlled Phase 2 trial. The company said the site addition strengthens trial execution and data quality as CALMA advances.

Argus Jan 22 session

+7.31% close to close Open Argus

Details

News Market Reaction – IGC

On Jan 22, the day this news came out, IGC closed 7.31% above the previous close.

Data tracked by StockTitan Argus for the Jan 22 session.

Market Context

On Jan 22, the day this news came out, the stock closed 7.3% above the previous close. A strong posi...

Analysis

On Jan 22, the day this news came out, the stock closed 7.3% above the previous close. A strong positive reaction aligns with IGC’s pattern of using clinical updates to reinforce progress in the CALMA Phase 2 program, even as the stock trades 43.71% below its 52-week high and under its $0.34 200-day MA. Investors have recently absorbed a dilutive 779,997-share offering and an active resale shelf covering 978,235 shares, factors that could temper follow-through if enthusiasm fades.

Key Figures

Registered direct shares: 779,997 shares Offering price: $0.30 per share Gross proceeds: $234,000 +5 more

Registered direct shares

779,997 shares

Registered direct offering disclosed Jan 5, 2026

Offering price

$0.30 per share

Registered direct offering for common stock

Gross proceeds

$234,000

Expected gross from Jan 5, 2026 direct offering

Quarterly revenue

$191 thousand

Quarter ended Sep 30, 2025 (Form 10-Q)

Net loss

$1.821 million

Quarter ended Sep 30, 2025 (Form 10-Q)

Cash and equivalents

$1.105 million

As of Sep 30, 2025 (Form 10-Q)

Short interest

0.46%

Reported short percent of float

Enrollment milestone

65% enrolled

CALMA Phase 2 trial as of Dec 9, 2025

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Trial site expansion

   24h Move

   -0.1%

   Added Dominion Medical Associates as a CALMA Phase 2 trial site.

2. Jan 06

   Reporting change

   24h Move

   -1.3%

   Aligned fiscal year with calendar year to aid U.S. investor comparability.

3. Jan 05

   Capital raise

   24h Move

   +0.6%

   Registered direct offering to fund IGC-AD1 Phase 2 and general purposes.

4. Dec 19

   Patent grant

   24h Move

   -10.7%

   USPTO issued patent for microdose-based cannabinoid treatment for tics.

5. Dec 15

   Policy positioning

   24h Move

   -3.9%

   Outlined potential benefits from federal momentum toward Schedule III status.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

central nervous system, cns, randomized, double-blind, placebo-controlled, cannabinoid-based

4 terms

central nervous system medical

"studies across a broad range of Central Nervous System ("CNS") disorders"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"Central Nervous System ("CNS") disorders, including Alzheimer's disease"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

randomized, double-blind, placebo-controlled medical

"being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

cannabinoid-based medical

"IGC-AD1 is an investigational cannabinoid-based investigational therapy"

Cannabinoid-based describes products, medicines, or technologies built around cannabinoids — chemical compounds originally found in cannabis plants or their synthetic equivalents — as the primary active ingredient. Investors care because these offerings carry specific market opportunities and risks tied to regulation, clinical proof, intellectual property and public acceptance; think of cannabinoids as the key ingredient in a recipe that can drive sales if safe and legal, or limit them if not.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -

POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.

Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System ("CNS") disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.

"Adding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders," said Ram Mukunda, CEO of IGC Pharma. "Their experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1."

Located at 2409 Ocean Avenue, Unit 1F, Brooklyn, New York, Integrative Clinical Trials expands IGC Pharma's presence in a major metropolitan area with access to a diverse patient population. The Company believes that incorporating sites with broad CNS experience is important to supporting enrollment and patient engagement.

IGC-AD1 is an investigational cannabinoid-based investigational therapy being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial for agitation in patients with Alzheimer's disease. The continued expansion of the CALMA trial's clinical footprint reflects IGC Pharma's strategy to support enrollment and maintain rigorous clinical oversight.

To learn more about the trial and participation, visit https://igcpharma.com/igc-ad1-phase-ii/.

About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IGC (IGC) announce on January 22, 2026 about the CALMA Phase 2 trial?

IGC announced that Integrative Clinical Trials in Brooklyn, New York, joined the Phase 2 CALMA trial as a new clinical site for IGC-AD1.

Who is the principal investigator at the new IGC CALMA site in Brooklyn?

The principal investigator is Dr. Inna Yuryev-Golger, MD.

How does the new Integrative Clinical Trials site affect IGC-AD1 enrollment for IGC's CALMA trial?

The company expects the Brooklyn site to support enrollment and patient diversity due to its CNS research experience in a major metropolitan area.

What type of study is IGC-AD1 being evaluated in for IGC's CALMA trial?

IGC-AD1 is being evaluated in a randomized, double-blind, placebo-controlled Phase 2 trial for agitation in Alzheimer's disease.

Where is the new Integrative Clinical Trials site located for IGC's CALMA study?

The site is located at 2409 Ocean Avenue, Unit 1F, Brooklyn, New York.

How can potential participants learn more about the IGC-AD1 Phase 2 CALMA trial (IGC)?

Visit the trial information on the company's website at the IGC-AD1 Phase II trial page.